Clinical Trial Search

Primary: Mean Change From Baseline in the Monthly (28 Day) Average Number of Headache Days of at Least Moderate Severity During the 12-week Period After the First Dose of…

Primary: Percentage of Participants With a ≥ 50% Decrease From Baseline in the Frequency of Headache Days — 40.0; 12.0 percentage of participants — p=<0.001

Primary: Percent Change of Headache Days Compared to Baseline — -13.50; -36.50 percent change of headache days

Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month

Primary: Change in the Number of Moderate to Severe Headache Days Within a 28 Day Average Period in Six Months Compared to Baseline — 4.4; 4.7 Moderate to severe headache days…

Primary: Incidence Rate of Dysphagia — 0.4 events per 1,000 person-months

Primary: Percentage of Subjects With at Least One Treatment-Emergent Adverse Event (TEAE) — 92.0; 88.0 percentage of participants

Primary: Change From Baseline in Frequency of Headache Days — -3.12 days per 28-days — p=<0.001

Primary: Percentage of Participants Admitted to the Hospital for Headache — 6.0; 2.1 percentage of participants

Primary: Change From Baseline in Monthly Migraine Days — -4.18; -6.64; -6.63 migraine days / month — p=<0.001

Primary: Change in Number of Migraine Episodes Per 30 Days at Month 10. — -2.1; -2.1; -2.2; -3.3 Number of Migraine episodes — p=< .01

Primary: Mean Change From Baseline in the Number of Monthly Cumulative Headache Hours of Any Severity on Headache Days Relative to the 28-day Post-treatment Period Ending With…

Primary: Change From Baseline in Monthly Migraine Days — -8.2; -7.7; -5.6 Migraine Days — p=<0.0001

Primary: Mean Change From Baseline in the Monthly (28 Days) Average Number of Migraine Days During the 12-week Period After the First Dose of Investigational Medicinal Product…

Primary: Change From Baseline in the Monthly Average Number of Headache Days of At Least Moderate Severity During the 12-Week Period After the First Dose of Study Drug — -2.5…

Primary: Proportion of Patients With Treatment Discontinuation Due to an Adverse Event (AE) During the Double-blind Treatment Epoch/Period (DBTE) — 41; 151 Participants — p=<.001

Primary: Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHD) — -2.74; -4.83; -4.62 Migraine Headache Days per Month — p=<.001

Primary: A Change in the Frequency of Cluster Headache Attacks Per Week — -2.0; -7.6 CH attacks per week

Primary: Adjusted Mean Change From Baseline in the Number of Migraine Headache Days (MHD) During the Last 4 Weeks of Treatment Prior to Taper — -3.8; -3.6; -3.8; -3.3 Migraine…

Primary: DB Period: Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab — -0.6; -3.7; -4.1 days/month…

Primary: Number of Participants With Adverse Events (AEs) — 365; 456; 365; 426 Participants

Primary: Change From Baseline in Mean Monthly Migraine Days (MMD) Over Months 4, 5, and 6 of the Double-blind Treatment Period — -1.98; -3.60 migraine days / month — p=<0.001

Primary: Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT Population — -4.63; -7.13; -7.27 migraine days per month — p=0.0001

Primary: 75% Migraine Responder Rate — 38; 37; 33; 33 Participants — p=0.0330

Primary: Frequency of Moderate to Severe Headache Days — 9.3; 9.1 days

Primary: Number of Migraine Attacks in Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate — 1.35; 2.12 Migraine attacks

Primary: Number of Participants With Adverse Events — 398; 302; 34; 0 Participants

Primary: Visual Analog Scale — 8.1; 7.9; 7.9; 5.9 score on a scale

Primary: Mean Change From Baseline in the Number of Migraine Headache Days in the Last 28-day Period of the 12-week Treatment Phase — -4.2; -3.0 Migraine headache days

Primary: Safety - Number of Participants With Adverse Events — 6; 5 Participants